跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Grifols Therapeutics, Inc.

首页临床试验发起方与机构Grifols Therapeutics, Inc.

Grifols Therapeutics, Inc.

ACTIVE

北卡罗来纳州韦克县, 北卡罗来纳州, 美国Subsidiary

隶属于 talecris biotherapeutics holdings corp.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

27

27 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

26

96.3%

试验状态分布

进行中（未招募）

27

100.0%

相关临床试验

该机构主办的试验（27）

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

Sep 201860 名受试者

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

May 201760 名受试者

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

Dec 201661 名受试者

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

Mar 201660 名受试者

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

Feb 201660 名受试者

A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

进行中（未招募）

Feb 201660 名受试者

A study investigating Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the treatment of patients with Myasthenia Gravis. The patients will receive 2g/kg of IP as a loading dose. The loading dosage is followed by maintenance doses of 1 g/kg administered every third week until Visit 8 (Week 21).

进行中（未招募）

Jan 201662 名受试者

A study investigating Immune Globuline (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the treatment of patients with Myasthenia Gravis, dependent on Corticosteroids. The patients will receive 2g/kg of IP as a loading dose. The loading dosage is followed by maintenance doses of 1 g/kg administered every third week until Visit 13 (Week 36). During maintenance doses the investigator will try to slowly reduce the patient's corticosteroid dose.

进行中（未招募）

Jan 201660 名受试者

第 1 页，共 4 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验27
药物批准
资讯

返回机构列表